Hepatitis

Feature Article

ID Specialist Involvement Key to Successfully Treating Hepatitis C

ID Specialist Involvement Key to Successfully Treating Hepatitis C

ID specialists need to take a major role in the implementation of new treatments for HCV.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News

Abnormal Bone Metabolism With Tenofovir for HBV Infection

Abnormal Bone Metabolism With Tenofovir for HBV Infection

Long-term treatment with tenofovir for hepatitis B virus infection is associated with hypophosphatemia and elevated serum levels of fibroblast growth factor 23, a hormone that induces renal phosphate excretion.

Clinical Guideline on Evaluating Abnormal Liver Chemistries

Clinical Guideline on Evaluating Abnormal Liver Chemistries

The American College of Gastroenterology released a set of guideline for evaluating abnormal liver chemistries.

FDA Expands Indication, Adds Boxed Warning for HCV Drug

FDA Expands Indication, Adds Boxed Warning for HCV Drug

FDA expanded indication for Technivie (ombitasvir, paritaprevir, ritonavir; AbbVie) and added a boxed warning for treatment of patients with HCV infection with compensated cirrhosis.

Low Rates of HCV Testing Seen in Baby Boomers

Low Rates of HCV Testing Seen in Baby Boomers

Of 76.2 million baby boomers in the US in 2015, only 10.5 million had been tested for hepatitis C, according to new research.

Anti-HBs Protect Against HBV Reactivation During Chemotherapy

Anti-HBs Protect Against HBV Reactivation During Chemotherapy

Meta-analysis provides further support to findings that show a protective role of antibody to hepatitis B surface antigen against reactivation in patients with resolved HBV undergoing chemotherapy for hematologic tumors without antiviral prophylaxis.

Liver Cancer Rates With Interferon-Free Regimens in HIV/HCV

Liver Cancer Rates With Interferon-Free Regimens in HIV/HCV

The incidence of hepatocellular carcinoma after sustained virological response has not increased with the widespread use of all oral direct antivirals regimens as suggested in previous studies, according to a new study.

French Study Points to Eradication of HIV-HCV Coinfection

French Study Points to Eradication of HIV-HCV Coinfection

Prevalence of active HIV-HCV coinfection may decrease to 1.1% in France over the next decade.

Antivirals Effective in Patients With HCV Infection and Hemophilia

Antivirals Effective in Patients With HCV Infection and Hemophilia

A phase 2b trial showed that direct-acting antivirals were effective for treating hepatitis C virus infection in patients with inherited bleeding disorders.

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

While direct-acting antivirals represent an important advance in the treatment of hepatitis C virus infection, further investigation is needed to understand the reasons for the cases of liver failure and antiviral failure reported to the FDA.

HCV Infection Linked to Nonhepatic Cancers in the Elderly

HCV Infection Linked to Nonhepatic Cancers in the Elderly

In the elderly population, hepatitis C virus infection is associated with cancers other than hepatocellular carcinoma, such as bile duct and pancreatic cancers and diffuse large B-cell lymphoma.

Sign Up for Free e-newsletters